X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (848) 848
Book Review (145) 145
Publication (66) 66
Book Chapter (10) 10
Conference Proceeding (10) 10
Dissertation (3) 3
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
deferasirox (787) 787
index medicus (545) 545
humans (472) 472
hematology (338) 338
iron overload (289) 289
deferoxamine (286) 286
male (280) 280
iron chelating agents - therapeutic use (263) 263
female (261) 261
deferiprone (230) 230
iron (192) 192
iron overload - drug therapy (192) 192
thalassemia (187) 187
benzoates - therapeutic use (182) 182
beta-thalassemia (181) 181
triazoles - therapeutic use (181) 181
adult (175) 175
chelation therapy (139) 139
oncology (138) 138
overload (136) 136
middle aged (122) 122
adolescent (121) 121
iron overload - etiology (119) 119
therapy (119) 119
icl670 (114) 114
child (112) 112
iron chelation (111) 111
ferritin (110) 110
myelodysplastic syndromes (110) 110
chelation (105) 105
treatment outcome (102) 102
iron chelating agents - adverse effects (100) 100
iron chelating agents - administration & dosage (98) 98
ferritins - blood (96) 96
benzoates - administration & dosage (95) 95
triazoles - administration & dosage (95) 95
serum ferritin (93) 93
benzoates - adverse effects (92) 92
triazoles - adverse effects (92) 92
young adult (90) 90
transfusion reaction (89) 89
safety (88) 88
aged (87) 87
blood transfusion (87) 87
thalassemia major (87) 87
anemia (85) 85
pharmacology & pharmacy (85) 85
chelation-therapy (83) 83
efficacy (82) 82
desferrioxamine (81) 81
iron - metabolism (81) 81
beta-thalassemia - drug therapy (74) 74
child, preschool (73) 73
animals (72) 72
transfusion (71) 71
pediatrics (70) 70
survival (70) 70
deferoxamine - therapeutic use (69) 69
medicine & public health (69) 69
care and treatment (68) 68
iron chelating agents - pharmacology (67) 67
myelodysplastic syndrome (67) 67
analysis (66) 66
beta-thalassemia major (64) 64
magnetic-resonance (64) 64
myocardial iron (62) 62
iron chelation therapy (61) 61
benzoates - pharmacology (59) 59
triazoles - pharmacology (58) 58
biochemistry & molecular biology (55) 55
pyridones - therapeutic use (55) 55
retrospective studies (55) 55
children (52) 52
sickle-cell-disease (51) 51
liver (50) 50
oxidative stress (50) 50
aged, 80 and over (49) 49
beta-thalassemia - complications (47) 47
chelation therapy - methods (46) 46
labile plasma iron (46) 46
disease (45) 45
management (45) 45
health aspects (43) 43
myelodysplastic syndromes - complications (43) 43
complications (42) 42
magnetic resonance imaging (42) 42
myelodysplastic syndromes - therapy (42) 42
cardiac iron (41) 41
iron overload - blood (41) 41
medicine, general & internal (41) 41
risk factors (41) 41
iron overload - metabolism (40) 40
toxicity (40) 40
transfusional iron overload (40) 40
patients (39) 39
research (39) 39
trial (39) 39
diagnosis (37) 37
iron - blood (37) 37
liver - metabolism (37) 37
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (825) 825
French (12) 12
German (10) 10
Korean (4) 4
Spanish (4) 4
Polish (3) 3
Chinese (2) 2
Portuguese (2) 2
Indonesian (1) 1
Persian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Transfusion and Apheresis Science, ISSN 1473-0502, 08/2019, Volume 58, Issue 4, pp. 429 - 433
Iron chelators are extensively used to reduce iron overload. Our purpose was to compare effects of deferasirox versus deferasirox and deferoxamine in patients... 
Deferasirox | Chelation | Thalassemia | Iron | Deferoxmaine
Journal Article
Journal Article
BLOOD, ISSN 0006-4971, 04/2012, Volume 119, Issue 14, pp. 3263 - 3268
This was a 24-week, multicenter phase-2 study designed to assess safety, tolerability, and pharmacodynamics of FBS0701, a novel oral chelator, in adults with... 
DEFERASIROX ICL670 | THERAPY | BETA-THALASSEMIA | HEMATOLOGY
Journal Article
Indian Pediatrics, ISSN 0019-6061, 04/2012, Volume 49, Issue 4, pp. 268 - 269
Journal Article
British Journal of Haematology, ISSN 0007-1048, 2019
Patients with low-risk myelodysplastic syndromes (MDS) usually develop iron overload. This leads to a high level of oxidative stress in the bone marrow (BM)... 
iron overload | deferasirox | DNA damage | myelodysplastic syndromes | reactive oxygen species
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, pp. e0208102 - e0208102
Chronic blood transfusions are responsible to cause iron overload, which leads to several complications to end organs and osteoporosis. Iron chelation is... 
OVERLOAD | THERAPY | METABOLISM | EFFICACY | DEFERASIROX | MULTIDISCIPLINARY SCIENCES | DISEASE | Thalassemia - therapy | Deferasirox - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Iron Overload - drug therapy | Humans | Transfusion Reaction - complications | Drug Evaluation | Transfusion Reaction - drug therapy | Leukocytes, Mononuclear | Healthy Volunteers | Osteoporosis - etiology | Bone and Bones - drug effects | Iron Overload - blood | Iron - analysis | Blood Transfusion | Ferritins - blood | Bone and Bones - metabolism | Thalassemia - complications | Transfusion Reaction - blood | Adult | Deferasirox - pharmacology | Female | Cell Differentiation | Osteoclasts - physiology | Pyrazoles - pharmacology | Hydrazines - pharmacology | Hydrazines - therapeutic use | Iron Chelating Agents - therapeutic use | Osteoporosis - prevention & control | Iron - metabolism | Receptors, Thrombopoietin - antagonists & inhibitors | Iron Overload - complications | Iron Chelating Agents - pharmacology | Benzoates - pharmacology | Primary Cell Culture | Osteoclasts - drug effects | Osteoporosis | Blood transfusion | Investigations | Pediatrics | Transfusion | Hemodialysis | Liver | Infections | Iron | Phosphatase | Tissues | Blood | Thrombopoietin | Hepatitis | Surgery | Chelation | Biocompatibility | Chronic illnesses | Thrombocytopenia | Complications | Organs | Thalassemia | Metabolism | Chelation therapy | Medicine | Bone mass | Osteoclasts | Acid phosphatase (tartrate-resistant) | Bone | Index Medicus
Journal Article
Journal of China Pharmaceutical University, ISSN 1000-5048, 06/2016, Volume 47, Issue 3, pp. 288 - 290
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2011, Volume 154, Issue 3, pp. 387 - 397
To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To... 
Deferasirox | Exjade | Iron overload | Sickle cell disease | Oral iron chelator
Journal Article
ChemMedChem, ISSN 1860-7179, 08/2019, Volume 14, Issue 16, pp. 1466 - 1466
The Front Cover depicts two horses (taken by the lead author J.S.) that look like they are “joined at the hips.” Although they look “connected,” each horse... 
antioxidant | Niemann–Pick | protein aggregation | deferasirox | iron complexes
Journal Article
Journal of Luminescence, ISSN 0022-2313, 05/2014, Volume 149, pp. 251 - 257
Journal Article
Journal Article
Pharmacogenomics Journal, ISSN 1470-269X, 05/2018, Volume 18, Issue 3, pp. 506 - 515
beta-Thalassemia patients develop deficiency in vitamin D absorption and liver hydroxylation, resulting in extremely low calcitriol levels. We explored the... 
CHELATION-THERAPY | D METABOLISM | PROSTATE-CANCER | GENETICS & HEREDITY | 25-HYDROXYVITAMIN D | VITAMIN-D-RECEPTOR | D-BINDING PROTEIN | PHARMACOLOGY & PHARMACY | BETA-THALASSEMIA | THALASSEMIA MAJOR | SINGLE-NUCLEOTIDE POLYMORPHISMS | DEPENDENT IRON OVERLOAD | beta-Thalassemia - pathology | Vitamin D3 24-Hydroxylase - genetics | Humans | Middle Aged | Vitamin D Deficiency - drug therapy | beta-Thalassemia - genetics | Male | Deferasirox - adverse effects | Receptors, Calcitriol - genetics | Young Adult | Vitamin D - genetics | Liver - drug effects | Vitamin D Deficiency - pathology | Adult | Female | Vitamin D Deficiency - genetics | Liver - metabolism | Deferasirox - administration & dosage | Genotype | Treatment Outcome | Deferasirox - blood | beta-Thalassemia - drug therapy | Vitamin D-Binding Protein - genetics | Adolescent | Alleles | Vitamin D - metabolism | Polymorphism, Single Nucleotide | Pharmacogenetics | Transcription factors | Pharmacology, Experimental | Cytochrome P-450 | Genetic aspects | Research | Pharmacokinetics | Health aspects | Chelation therapy | Genetic polymorphisms | Nutrient deficiency | Gc gene | Hydroxylation | Liver | Calcitriol | Thalassemia | Pharmacology | Single-nucleotide polymorphism | Liquid chromatography | CDX2 protein | Regression analysis | Metabolism | High-performance liquid chromatography | Patients | Vitamin D | Cutoffs | Vitamin D receptors | High performance liquid chromatography | Extreme values | Polymorphism | 25-Hydroxyvitamin D | Index Medicus
Journal Article
International Journal of Research in Pharmaceutical Sciences, 12/2017, Volume 8, Issue 4, pp. 512 - 517
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 05/2019, Volume 63, Issue 5
There has been renewed interest in combining traditional small-molecule antimicrobial agents with nontraditional therapies to potentiate antimicrobial effects.... 
Klebsiella | antibiotic resistance | fluoroquinolone | DEFERASIROX | transferrin | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | IRON | ciprofloxacin
Journal Article
Bioorganic Chemistry, ISSN 0045-2068, 06/2019, Volume 87, pp. 720 - 727
Structure of compound and docking models of the in AChE (PDB code: ). A series of compounds following the lead compounds including deferasirox and tacrine were... 
Deferasirox | Acetylcholinesterase inhibitors | Multifunctional agents | Alzheimer's disease | Metal chelator | Tacrine
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.